Wolfe Research Upgrades CVS Health to Outperform, Announces $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Justin Lake has upgraded CVS Health (NYSE:CVS) from Peer Perform to Outperform and set a price target of $80.
September 12, 2023 | 9:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CVS Health has been upgraded to Outperform by Wolfe Research, with a new price target of $80.
The upgrade from Wolfe Research is a positive signal for CVS Health. It indicates that the analyst believes the company will outperform its peers in the market. The new price target of $80 also suggests that the analyst sees potential for the stock's price to increase. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100